Live Breaking News & Updates on Neostem Inc

Stay updated with breaking news from Neostem inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lisata Therapeutics (NASDAQ:LSTA) vs. Mangoceuticals (NASDAQ:MGRX) Head to Head Analysis

Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) and Mangoceuticals (NASDAQ:MGRX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends. Earnings and Valuation This table compares Lisata Therapeutics […] ....

New Jersey , United States , Cohen Enterprises Inc , Lisata Therapeutics Inc , Caladrius Biosciences Inc , Mangoceuticals Inc , Neostem Inc , Lisata Therapeutics , Get Free Report , Given Lisata Therapeutic , Caladrius Biosciences , Basking Ridge , Cohen Enterprises , Lisata Therapeutics Daily , Nasdaq Lsta , Stock Comparison , Stock Analysis ,

Analyzing Lisata Therapeutics (LSTA) & Its Competitors

Lisata Therapeutics (NASDAQ:LSTA – Get Rating) is one of 19 publicly-traded companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it contrast to its competitors? We will compare Lisata Therapeutics to similar companies based on the strength of its dividends, institutional ownership, analyst recommendations, profitability, earnings, valuation and risk. […] ....

New Jersey , United States , Caladrius Biosciences Inc , Neostem Inc , Lisata Therapeutics Company Profile , Lisata Therapeutics Inc , Lisata Therapeutics , Get Rating , Lisata Therapeutic , Given Lisata Therapeutic , Caladrius Biosciences , Basking Ridge , Lisata Therapeutics Daily , Nasdaq Lsta , Stock Comparison , Stock Analysis ,

Caladrius Biosciences (NASDAQ:CLBS) Rating Increased to Buy at Zacks Investment Research

Caladrius Biosciences (NASDAQ:CLBS – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday, Zacks.com reports. The firm presently has a $0.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 8.65% from the stock’s […] ....

New York , United States , Caladrius Biosciences , Caladrius Biosciences Inc , Geode Capital Management , Goldman Sachs Group Inc , Zacks Investment Research , Neostem Inc , Sigma Securities , Caladrius Biosciences Company Profile Get Rating , Barclays Plc , Millennium Management , Get Rating , Investment Research , Capital Management , Goldman Sachs Group , Biosciences Company Profile , Nasdaq Clbs ,